SEC Form 4 · accession 0001209191-18-003485

Atara Biotherapeutics, Inc. · ATRA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP & Chief Financial Officer

Period of report

Jan 11, 2018

Accepted (ET)

Jan 12, 2018 · 7:56 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001604464

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F2	Jan 11, 2018	S	3,500	$20.77	D	93,154	D
Common Stock	Jan 12, 2018	M	30,000	$11.00	A	123,154	D
Common Stock^F3	Jan 12, 2018	S	3,500	$22.32	D	119,654	D
Common Stock^F4	Jan 12, 2018	S	30,000	$25.00	D	89,654	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F5	$11.00	Jan 12, 2018	M	30,000	D	—	Oct 14, 2021	Common Stock	30,000	10,000	D

F1Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016.
F2The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.70 to $20.925. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.15 to $22.35. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4The price in Column 4 is a weighted average sale price. The prices actually received ranged from $25.00 to $25.025. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F51/48th of the shares subject to the stock option vest and become exercisable each month following October 15, 2014.